Striatal dopamine signaling is differentially regulated along the dorso-ventral axis, but how these differences are encoded by dopamine receptors is unknown. In this issue of Neuron, Marcott et al. (2018) show that dopamine activates D2 receptors in regionally distinct ways and dissect the underlying mechanisms behind striatal D2 heterogeneity.
In the striatum, dopamine release shapes reward-seeking behavior and motor control, and its dysregulation is implicated in disorders ranging from addiction to schizophrenia (Graybiel and Mink, 2009) . Two distinct populations of midbrain neurons release dopamine into the striatum: the dorsal striatum (DStr) receives dopaminergic inputs predominately from the substantia nigra (SNc) and the ventral striatum/nucleus accumbens (NAc) from the ventral tegmental area (VTA). Along with different afferents, the striatal subdivisions diverge in their efferent connectivity and are thus positioned to influence diverse behaviors. Dopamine release is also differentially regulated in the striatal compartments, but how these differences are captured by dopamine receptors on striatal projection neurons is unknown. To dissect disease mechanisms associated with dopaminergic dysregulation, we must first determine how dopamine acts on its receptors in specific striatal subdivisions.
In this issue of Neuron, Marcott et al. (2018) tackle this question by exploring how dopamine signaling is encoded by D2 receptors (D2Rs) in striatal medium spiny neurons (MSNs). They first confirm that dopamine concentrations are differently regulated in striatal subregions with fast-scan cyclic voltammetry. Like prior reports, dopamine release and uptake are greater in DStr than NAc ( Figure 1A ). To examine how differences in release are encoded, Marcott et al. (2018) use a trick, by overexpressing a G-proteincoupled inward-rectifying potassium (GIRK) channel to measure D2R activation. Normally, GIRK2 acts downstream of G i/o -coupled receptors, including D2R. This clever approach allows potassium conductance to be used as a receptor activation sensor, measured as D2R-mediated inhibitory postsynaptic currents (D2-IPSCs). Marcott et al. (2018) first confirm that GIRK2-overexpressionmediated D2-IPSCs occur exclusively in D2-MSNs, consistent with the inability of GIRK to signal with G s -coupled receptors, including D1R. In a series of elegant whole-cell voltage-clamp recordings, Marcott et al. (2018) use this sensor to show that NAc D2Rs activate and decay more slowly than DStr D2Rs despite similar dopamine release kinetics between NAc and DStr ( Figure 1A) .
To explore the mechanism behind differential activation kinetics, Marcott et al. (2018) manipulate local dopamine dynamics. They show that differences in dopamine concentrations are not responsible for different D2R activation kinetics, since D2-IPSCs reach similar amplitudes at different rates in NAc MSNs and DStr MSNs using iontophoresed dopamine or low-intensity stimulation. Although dopamine clearance is linked to D2R decay rate, neither pharmacologic blockade nor knockout (KO) of dopamine transporter DAT explains the difference in D2R activation kinetics between striatal divisions. Together, this suggests that despite native differences in dopamine release and uptake, these parameters alone are not responsible for the differences in D2R activation rate. Differential kinetics are also independent of D2R availability since partial D2R blockade does not change activation rate in DStr or NAc MSNs. With obvious extracellular mechanistic candidates eliminated, Marcott et al. (2018) turned to intracellular regulatory molecules. Regulator of G protein signaling (RGS) and G-proteincoupled receptor kinases (GRKs) can control the timing and termination of G-protein-coupled receptor (GPCR) signaling. Through KO and pharmacologic manipulation, Marcott et al. (2018) show that RGS7/9, but not GRK2/3, regulate D2R kinetics and may partially explain regional differences.
In addition to differences in kinetics, Marcott et al. (2018) also determine that NAc MSN D2Rs are more sensitive to dopamine. Smaller concentrations elicit maximal D2R activation in NAc compared to DStr, aligning with differences in dopamine release between the two regions ( Figure 1A ). NAc D2Rs can be saturated by lower dopamine concentrations, thus when D2-IPSCs are evoked over a background of bath-applied dopamine, NAc D2Rs cannot respond with the same amplitude as DStr D2Rs. This suggests that under conditions of high tonic dopamine, D2Rs in DStr MSNs may have a greater ''signal-to-noise ratio'' since phasic release is more readily detected over a high tonic background. D2Rs expressed on local axon collaterals also differ in sensitivity between NAc and DStr, suggesting that regional differences are not restricted to dendritic D2Rs.
Ga subunit composition can determine GPCR sensitivity, and differences in Ga expression may control the differences in D2R sensitivity. Marcott et al. (2018) confirm that dopamine more potently activates Ga o compared to Ga i ( Figure 1B) . They then show that conditional KO of Ga o in NAc reduces D2R dopamine sensitivity to that of DStr D2Rs, suggesting that D2Rs in NAc may be more readily coupled to Ga o and thus have greater sensitivity. Reduced sensitivity of NAc D2Rs is recapitulated in cocaine-exposed mice, indicating that D2R Ga subunits may also control D2R dopamine sensitivity after cocaine ( Figure 1A) .
Finally, D2Rs are not the only Gi /ocoupled GPCRs in the striatum. Marcott et al. (2018) determine that regional heterogeneity is restricted to D2Rs, since G i/o -coupled opioid and M4 receptors in DStr and NAc do not differ in activation kinetics or agonist sensitivity in drug-naive mice. Intriguingly, drug exposure appears to abolish some regional differences in D2Rs. Chronic cocaine reduces NAc D2R dopamine sensitivity such that it more closely resembles DStr D2R sensitivity. There may be a unique molecular mechanism driving changes specifically to NAc D2Rs since drug exposure does not reduce DStr D2R sensitivity. This could occur at the transcriptional level, where methyltransferases, such as H3K9me3 or G9a, can regulate D2R expression or by alternative splicing to modify Ga subunits and their downstream signaling cascades (Pierce et al., 2018) . If epigenetic modifications drive regionspecific D2R changes, studying them may provide information on altered dopaminergic function at both receptor and circuit level.
Moving forward, there are several factors that should be considered. First, dopamine release differs between striosome and matrix compartments of the striatum, and cocaine enhances dopamine to a greater extent in DStr striosomes compared to matrix (Salinas et al., 2016) . Since dopamine release is compartmentally altered by cocaine in DStr, D2Rs may respond with a change in sensitivity specifically in striosomes that was undetected by the current study. Second, Marcott et al. (2018) show that differences in DStr and NAc D2Rs are found in dendrites and axons of striatal MSNs. However, D2Rs expressed on interneurons or expressed presynaptically on dopamine terminals may also exhibit regional differences in sensitivity or kinetics. Presynaptic D2Rs differentially control dopamine release from SNc and VTA dopamine neurons (Fox et al., 2016) , which may result from the different Ga coupling proposed to occur postsynaptically. Differences in both pre-and postsynaptic D2R signaling are important to consider in dopaminergic circuitry since striato-nigro-striatal loops may depend on such specificities. These spiraling pathways support communication between midbrain dopamine structures and striatal regions to associate limbic and motor aspects of behavior. Interestingly, dorsal tier midbrain dopamine neurons have low D2R mRNA while ventral tier have higher D2R mRNA expression (Haber and Knutson, 2010) . By regionally altering presynaptic D2R-Ga coupling, cocaine could alter the transfer of information from NAc to DStr and promote habit formation and addiction. To understand how dopamine acts on D2-MSNs to drive addiction, further work is needed to dissect precisely how striatal D2Rs couple to Ga i/o in both drug-exposed and drugnaive animals. These future studies should (1) rely on quantitative methods to establish regional differences in Ga coupling on MSNs and dopamine terminals, (2) make use of intersectional tools that could allow for effective Ga subunit null mutations in specific D2-MSN populations in each subregion, and (3) establish how manipulating Ga coupling in the striatum can drive the acquisition of drug selfadministration or drug relapse. In addition to Ga coupling, it is important to consider that the transition from goal-directed to habitual drug taking also relies on striatal D2R-A2AR heterodimers. Following cocaine self-administration, D2R-A2AR density is increased in the NAc, leading to greater antagonism of the inhibitory (anti-drug) actions of D2R homodimers. D2R-A2AR heterodimers are instead reduced in the DStr after cocaine, and the disappearance of antagonistic D2R-A2AR interaction is proposed to support habit formation (Pintsuk et al., 2016) . Thus, in addition to the differences in D2R Ga subunits proposed by Marcott et al. (2018) , regional differences in D2R-A2AR interaction might also support increased drug intake.
Beyond drug addiction, understanding dopamine receptor signaling will provide insight into brain diseases with regionally divergent dopaminergic adaptations. In Parkinson's disease (PD), progressive dopaminergic cell loss generates an imbalance between mesolimbic and nigrostriatal functions and changes D2R expression dynamically across the DStr. These effects are further pronounced after dopamine replacement therapy. While changes in DStr D2Rs support motor impairments, they could also be involved in reward dysfunction, as seen with impulse control disorders some PD patients develop. Preclinically, the motivation to self-administer a D2/3R agonist is positively correlated with DFosB expression in the DStr of rats, whereas in ''parkinsonian'' rats, motivation is correlated with DFosB expression in the NAc. Regardless of parkinsonian state, animals with fewer dopamine neurons have increased motivation to self-administer D2/3R agonists (Engeln et al., 2013) . In the parkinsonian state, regional heterogeneity in D2R sensitivity to dopamine may trigger differential downstream molecular alterations, such as DFosB, to cause motor and reward dysfunction.
Schizophrenia is also associated with altered striatal dopamine release and D2R function. Dopamine release is increased in the DStr and is associated with symptoms of hallucination, while release is reduced in the NAc and is associated with decreased cognitive function. Striatal D2R density is generally increased in schizophrenic patients, and it is postulated that increased dopamine release results in an overstimulation of D2R to generate psychotic symptoms. Preclinically, transgenic mice with striatal D2R overexpression have altered basal ganglia connectivity and cognitive deficits along with decreased tonic VTA firing (Simpson and Kellendonk, 2017) . Altered VTA firing may be responsible for decreased NAc dopamine release and associated cognitive symptoms. Although dopamine is decreased in the NAc, the relatively smaller concentrations of dopamine required to activate NAc D2Rs may indicate they can still be overstimulated to generate psychosis. Alternatively, low tonic dopamine in NAc may instead increase the ability of NAc D2Rs to respond to phasic dopamine release.
Changes in dopamine signaling and D2R expression along the dorso-ventral axis of the striatum clearly play a role in a wide range of pathologies. Moving forward, it would be useful to examine how D2R activation kinetics, sensitivity, and Ga coupling are altered in dopaminerelated disease states and contribute to symptomatology. Identification of compounds preferentially targeting Ga o over Ga i may enable us to manipulate specific populations of D2R expressing neurons, similar to recently described G s -biased agonists (Yano et al., 2018) . In this way, Ga i -biased ligands could more selectively modulate D2R activity in the DStr to address motor symptoms without the confounds of concurrent NAc receptor modulation.
In summary, Marcott et al. (2018) provide a thorough foundation for how D2Rs encode dopamine signaling throughout striatal subregions. Differences in the degree of D2R-Ga o coupling are proposed to support regionally distinct responses to dopamine. These findings are relevant for understanding basal ganglia function in both normal and pathologic states. While improving our understanding of disease pathophysiology, knowledge of how dopamine receptors encode dopamine release throughout striatal subregions could also lead to new treatment developments. In the future, it will be critical to assess whether similar D2R differences are found outside the striatum, as well as how dopamine signaling is transduced by its other receptors. Together, this will provide a clearer picture of how dopamine signaling is encoded throughout the central nervous system.
